Critical Care & Emergencies (all articles)
What’s the risk of dying from a fast-spreading COVID-19 variant?
7 Feb, 2021 | 21:21h | UTCWhat’s the risk of dying from a fast-spreading COVID-19 variant? – Nature
Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv
Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19
7 Feb, 2021 | 21:13h | UTC“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia
SR/MA: Colistin nephrotoxicity
5 Feb, 2021 | 01:21h | UTC
NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”
5 Feb, 2021 | 01:44h | UTC
Dialysis patients have 4-fold greater risk of dying from COVID-19
5 Feb, 2021 | 01:39h | UTCNews Release: Dialysis patients have 4-fold greater risk of dying from COVID-19 – Canadian Medical Association Journal
Original Study: COVID-19 in patients undergoing long-term dialysis in Ontario – Canadian Medical Association Journal
Randomized trial: Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension
4 Feb, 2021 | 01:18h | UTC
Commentary on Twitter
Does induced hypothermia/targetted temp management improve outcomes in patients with traumatic brain injury?
Maybe or maybe not
But this trial slow to cool, not very cool, underpowered and mod rate of dropout
Prob does not answer questionhttps://t.co/UGRFmUVNV0 pic.twitter.com/c0iDqj2l2e
— Graham Nichol (@grahamnichol) January 29, 2021
German 2021 guideline update on acute therapy and management of anaphylaxis
4 Feb, 2021 | 01:17h | UTC
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
4 Feb, 2021 | 01:39h | UTCInvited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
Meta-analysis: In patients undergoing major visceral/noncardiac surgery, perioperative goal-directed therapy fluid administration reduces complications but has no effect on mortality
3 Feb, 2021 | 01:24h | UTC
Randomized trial: Similar outcomes with Dexmedetomidine or Propofol for sedation in mechanically ventilated adults with sepsis
3 Feb, 2021 | 01:30h | UTCDexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Study finds recommended ICU sedatives equally safe, effective – Vanderbilt University Medical Center AND PulmCrit Wee – MENDS2: Fentanyl or fentanyl for sedation in mechanically ventilated adults with sepsis
Ambulatory management of pulmonary embolism: A comparison of two risk-stratification scores
2 Feb, 2021 | 01:11h | UTC
Resumption of cardiac activity after withdrawal of life-sustaining measures
2 Feb, 2021 | 01:09h | UTCResumption of Cardiac Activity after Withdrawal of Life-Sustaining Measures – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: When is ‘dead’ really dead? What happens after a person ‘flatlines’ – The Conversation
Post severe COVID-19, CT reveals potentially lifetime lung damage in one-thirds of patients
2 Feb, 2021 | 01:19h | UTCOriginal Study: Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia – Radiology
Randomized trial: Conservative fluid management strategy vs. usual care in participants after cardiac surgery
1 Feb, 2021 | 01:39h | UTC
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
New Updates to the Surviving Sepsis Campaign COVID-19 Guidelines
1 Feb, 2021 | 01:56h | UTCAdditional resources: COVID-19 Guidelines – Surviving Sepsis Campaign
Commentary on Twitter
New updates to the #SurvivingSepsis Campaign #COVID19 Guidelines! Includes new recommendations for therapeutics and defines severe vs critical COVID-19.
View the full update in @CritCareMed, more infographics, and recommendations table here: https://t.co/OUuOwGJCR4#SCCMSoMe pic.twitter.com/1RGckdvoIm
— SCCM (@SCCM) January 30, 2021
Management of diabetes and hyperglycemia in the hospital
29 Jan, 2021 | 01:34h | UTCManagement of diabetes and hyperglycaemia in the hospital – The Lancet Diabetes & Endocrinology (free for a limited period)
Commentary on Twitter
New #Review online: Management of diabetes and hyperglycaemia in the hospital https://t.co/TmWLwFpYaw #diabetes #hospital #inpatient #critical #intensive #protocols #pharmacotherapy #technology #COVID19 pic.twitter.com/Uzg2enBz4a
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) January 28, 2021
Acute Pancreatitis: A Review
28 Jan, 2021 | 01:20h | UTCAcute Pancreatitis: A Review – JAMA (free for a limited period)
Podcast: Acute Pancreatitis Part 1 of 2: Diagnosis
Podcast: Acute Pancreatitis Part 2 of 2: Treatment
Meta-analysis: Beta-blockers for traumatic brain injury
28 Jan, 2021 | 01:18h | UTCBeta-blockers for traumatic brain injury: a systematic review and meta-analysis – Journal of Trauma and Acute Care Surgery (link to abstract – $ for full-text)
[Preprint] Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19
28 Jan, 2021 | 01:49h | UTCEfficacy of Colchicine in Non-Hospitalized Patients with COVID-19 – medRxiv
Commentary on Twitter
The large colchicine RCT for covid is preprint published.
It shows some consistent directional benefit for major outcomeshttps://t.co/gxtyKnMqZ5
Since this is a pill, it's safe, cheap & an early intervention (as tested here, before hospital) these findings are very encouraging pic.twitter.com/uzTSkjftFp— Eric Topol (@EricTopol) January 27, 2021
Duration of culturable SARS-CoV-2 in hospitalized patients with Covid-19
28 Jan, 2021 | 01:47h | UTC
Editorial: Covid-19 controversies: the Tocilizumab chapter
28 Jan, 2021 | 01:46h | UTCCovid-19 controversies: the tocilizumab chapter – The BMJ
Related: Contradicting earlier trials, Tocilizumab did not improve outcomes, with signs of harm, in patients with severe Covid-19 (studies and commentaries)
DEVT, SKIP Trials Add Support for Omitting IV tPA Before Stroke Thrombectomy
27 Jan, 2021 | 01:01h | UTCDEVT, SKIP Trials Add Support for Omitting IV tPA Before Stroke Thrombectomy – TCTMD
Original studies and commentaries: Randomized trial: Endovascular treatment alone noninferior to intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke
Opinion: Monoclonal antibodies yet to show important clinical benefit in patients with Covid-19
27 Jan, 2021 | 01:23h | UTCSee also: PulmCrit Wee – Follow-up Bamlanivimab study unmasks statistical chicanery
[Press release – not published yet] Neutralizing antibodies bamlanivimab and etesevimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
27 Jan, 2021 | 01:22h | UTCCommentary: Lilly antibody combo therapy cuts risk of COVID-19 deaths – Reuters
Commentary on Twitter
1st Phase 3 trial results on #SARSCoV2 monoclonal antibody combination with very positive results
1035 patients: 11 (2%) v (7%) for death or hospitalization and 0 vs 10 deaths in high-risk patients, given early https://t.co/BXnwCd64O9 (press release).
Coincides w/ EUA criteria. pic.twitter.com/3MjE0XtEqF— Eric Topol (@EricTopol) January 26, 2021